Ivabradine Auxilto (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. Inhibiting this current slows the rate of depolarisation, resulting in a lower heart rate without decreasing the strength of heart muscle contraction.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s resting heart rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary titration.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Ivabradine Auxilto, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors. This means it does not influence blood pressure or contractility, making it useful when beta‑blockers are contraindicated or not tolerated.

Ivabradine Auxilto should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources to maintain product stability.

Ivabradine Auxilto is taken orally, usually with a glass of water. It is typically administered twice daily, but the exact schedule and timing relative to meals are determined by the prescribing clinician.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may affect the retina. Patients should be instructed to report any episodes of dizziness, fainting, or visual changes promptly.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, acute myocardial infarction, unstable angina, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with a resting heart rate below 70 bpm unless specifically directed by a physician.